Clinical evidence
Clinical outcomes that persist
The strongest current evidence relates to pediatric obesity treatment: a pragmatic clinical study comparing Evira-supported combined lifestyle treatment with matched conventional care in the Swedish BORIS quality register, followed up over three years.
- −0.30 BMI SDS
- Mean change after one year with Evira-supported treatment, compared with approximately −0.15 in matched conventional care. 107 children versus 321 children, adjusted for sex, age and degree of obesity at treatment start.
- 3 years
- Follow-up of the same cohort (428 patients) indicates the treatment effect was maintained at three years, with significantly fewer discontinuations.
These results relate to pediatric obesity treatment in Swedish care. They should not be read as evidence for populations or settings that have not been studied.